Published in Exp Ther Med on March 28, 2017
The epigenomics of cancer. Cell (2007) 30.91
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A (1996) 29.54
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
Epigenetic reprogramming in mammalian development. Science (2001) 13.42
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med (2008) 13.06
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
Multiple myeloma. N Engl J Med (2004) 10.81
Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet (2007) 9.88
Planning cancer control in Latin America and the Caribbean. Lancet Oncol (2013) 8.43
Epigenetic modifications and human disease. Nat Biotechnol (2010) 7.29
Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet (2007) 5.16
Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet (2001) 3.96
The quest for universal health coverage: achieving social protection for all in Mexico. Lancet (2012) 3.48
Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell (2010) 2.86
Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res (1999) 2.54
Targeting DNA methylation. Clin Cancer Res (2009) 2.45
SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood (2002) 2.34
Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood (2006) 1.95
Footprinting of mammalian promoters: use of a CpG DNA methyltransferase revealing nucleosome positions at a single molecule level. Nucleic Acids Res (2005) 1.94
The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia (2009) 1.93
Gene methylation in gastric cancer. Clin Chim Acta (2013) 1.63
Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma (2009) 1.63
SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood (2004) 1.61
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget (2014) 1.47
A prognostic DNA methylation signature for stage I non-small-cell lung cancer. J Clin Oncol (2013) 1.47
Relationships between chromatin organization and DNA methylation in determining gene expression. Semin Cancer Biol (1999) 1.47
JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol (2006) 1.47
Aging, methylation and cancer. Histol Histopathol (2000) 1.40
Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma. Haematologica (2013) 1.40
IMPLICATIONS OF GLOBAL PRICING POLICIES ON ACCESS TO INNOVATIVE DRUGS: THE CASE OF TRASTUZUMAB IN SEVEN LATIN AMERICAN COUNTRIES. Int J Technol Assess Health Care (2015) 1.39
DNA methylation changes in multiple myeloma. Leukemia (2004) 1.23
Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. J Invest Dermatol (2004) 1.11
Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma. Leukemia (2002) 1.09
Methylation in hMLH1 promoter interferes with its binding to transcription factor CBF and inhibits gene expression. Oncogene (2001) 1.08
Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br J Haematol (2002) 1.05
Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance. Clin Cancer Res (2008) 0.95
SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. Blood (2011) 0.94
The suppressor of cytokine signaling-1 is constitutively expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to interferon-alpha. Haematologica (2004) 0.93
STAT3 in Cancer-Friend or Foe? Cancers (Basel) (2014) 0.93
Immunomagnetic enrichment of CD138 positive cells from weakly infiltrated myeloma patients samples enables the determination of the tumor clone specific IgH rearrangement. Ann Hematol (2001) 0.92
Availability and affordability of new medicines in Latin American countries where pivotal clinical trials were conducted. Bull World Health Organ (2015) 0.90
De novo methylation of tumor suppressor gene p16/INK4a is a frequent finding in multiple myeloma patients at diagnosis. Leukemia (2000) 0.89
Different prognostic values of p15(INK4b) and p16(INK4a) gene methylations in multiple myeloma. Haematologica (2003) 0.87
p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies. Hematol J (2001) 0.86
Treatment of relapsed and refractory multiple myeloma. Haematologica (2016) 0.83
DNA demethylating antineoplastic strategies: a comparative point of view. Genes Cancer (2010) 0.83
SOCS-1 gene methylation is frequent but does not appear to have prognostic value in patients with multiple myeloma. Leukemia (2003) 0.82
Impact of global and gene-specific DNA methylation pattern in relapsed multiple myeloma patients treated with bortezomib. Leuk Res (2013) 0.80
Aberrant gene promoter methylation marking disease progression in multiple myeloma. Leukemia (2006) 0.79
p16 gene methylation lacks correlation with angiogenesis and prognosis in multiple myeloma. Cancer Lett (2004) 0.78
Thalidomide and Dexamethasone Induction Therapy Until Best Response in Recently Diagnosed Patients with Multiple Myeloma: Results From a Pilot Study. Rev Invest Clin (2015) 0.77